The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-10-20 DOI:10.1002/brb3.70074

Nana Zhang, Ziya Wang, Dongren Sun, Hongxi Chen, Hongyu Zhou

{"title":"The Risk of Exacerbation of Myasthenia Gravis After COVID-19 Omicron Infection","authors":"Nana Zhang, Ziya Wang, Dongren Sun, Hongxi Chen, Hongyu Zhou","doi":"10.1002/brb3.70074","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>The aim of this study is to ascertain whether COVID-19 Omicron infection is associated with exacerbations in these myasthenia gravis (MG) patients.</p>\n </section>\n \n <section>\n \n <h3> Result</h3>\n \n <p>In total, 289 MG patients (comprising 60% females, with an average age of 46 ± 15 years) were enrolled. A total of 80.9% of MG patients reported a COVID-19 infection, with the majority experiencing a benign course (88%). MG patients who experienced COVID-19 infection demonstrated a higher likelihood of MG exacerbation, compared to those without the infection (18.8% vs. 7.3%, <i>p</i> = 0.039). In the survival analysis, after adjusting for confounding factors, the hazard ratio (HR) for exacerbation post-infection was found to be 3.38 (95% CI 1.20–9.53, <i>p</i> = 0.021). Compared to the exacerbation rates observed in JTA21, an increase was noted in DTM23 among COVID-19-infected MG patients (4.4% vs. 17.2%, <i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The COVID-19 is the risk of MG exacerbation.</p>\n </section>\n </div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/brb3.70074","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"102","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/brb3.70074","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

The aim of this study is to ascertain whether COVID-19 Omicron infection is associated with exacerbations in these myasthenia gravis (MG) patients.

Result

In total, 289 MG patients (comprising 60% females, with an average age of 46 ± 15 years) were enrolled. A total of 80.9% of MG patients reported a COVID-19 infection, with the majority experiencing a benign course (88%). MG patients who experienced COVID-19 infection demonstrated a higher likelihood of MG exacerbation, compared to those without the infection (18.8% vs. 7.3%, p = 0.039). In the survival analysis, after adjusting for confounding factors, the hazard ratio (HR) for exacerbation post-infection was found to be 3.38 (95% CI 1.20–9.53, p = 0.021). Compared to the exacerbation rates observed in JTA21, an increase was noted in DTM23 among COVID-19-infected MG patients (4.4% vs. 17.2%, p < 0.001).

Conclusion

The COVID-19 is the risk of MG exacerbation.

Abstract Image

查看原文本刊更多论文

COVID-19 Omicron 感染后肌萎缩症恶化的风险

目的本研究旨在确定 COVID-19 Omicron 感染是否与重症肌无力（MG）患者病情加重有关。结果总共有 289 名重症肌无力患者（其中女性占 60%，平均年龄为 46 ± 15 岁）被纳入研究。共有80.9%的MG患者报告感染了COVID-19，其中大多数患者的感染过程为良性（88%）。与未感染 COVID-19 的 MG 患者相比，感染 COVID-19 的 MG 患者病情恶化的可能性更高（18.8% 对 7.3%，P = 0.039）。在生存分析中，对混杂因素进行调整后发现，感染后病情加重的危险比 (HR) 为 3.38（95% CI 1.20-9.53，p = 0.021）。与 JTA21 中观察到的病情恶化率相比，COVID-19 感染的 MG 患者的 DTM23 有所上升（4.4% vs. 17.2%，p < 0.001）。结论 COVID-19 增加了 MG 病情加重的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464